A promotional GSK-sponsored symposium invited three experts to discuss their main considerations when selecting an inhaled corticosteroid (ICS)/inhaled long-acting β2-agonist (LABA) combination for patients with moderate asthma. Ashley Woodcock, Professor of Respiratory Medicine, University of Manchester; and Consultant Physician at The North-West Lung Centre, Wythenshawe Hospital, Manchester, UK, explained why timely assessment is critical for ICS/LABA initiation.
In this issue
Rate this content's potential impact on patient outcomes
Average rating / 5. Vote count:
No votes so far! Be the first to rate this content.